Pediatric Dermatology News

Celebrity news and nutrition stories led Healio Dermatology’s most-read articles in August.

Eli Lilly and Company announced it received FDA approval for Ebglyss for the treatment of moderate-to-severe atopic dermatitis that is not well controlled with topical prescription therapies, according to a company press release.

The use of personal care products was associated with endocrine-disrupting chemicals called phthalates in children aged as young as 4 years, according to a study.

The FDA has issued a rare pediatric disease designation to Ilya Pharma for its topical emilimogene sigulactibac treatment for STING-associated vasculopathy with onset in infancy, according to a press release.

As kids return to school, the CDC has reminded the public that children with lice do not need to cut their school day short and be sent home early.

The FDA has granted rare pediatric disease designation to Descartes-08, an autologous mRNA cell therapy, for the treatment of juvenile dermatomyositis, Cartesian Therapeutics announced in a press release.

Children with diverse skin types with atopic dermatitis-prone skin did not experience any adverse events when using a sunscreen formulated with antioxidants, according to a study.

Since 1993, the American Academy of Dermatology has held a unique weeklong summer camp experience for kids aged 8 to 16 years with chronic skin conditions.

Otezla is now available in the U.S. for the treatment of moderate to severe plaque psoriasis in children and adolescents aged 6 years and older, Amgen announced in a press release.